Table 2 Clinical characteristics

Laterality (N = 39)

Unilateral

n = 21 (53.8%)

Alternating bilateral

n = 10 (25.64%)

Bilateral

n = 8 (20.51%)

Onset (N = 39)

Insidious

n = 21 (53.8%)

Sudden

n = 18 (46.2%)

Duration (N = 39)

Limited

n = 14 (35.9%)

Persistent

n = 18 (46.2%)

Course (N = 39)

Acute

n = 4 (10.3%)

Chronic

n = 9 (23.1%)

Recurrent

n = 26 (66.7%)

Anatomic location (N = 39)

Anterior

n = 30 (76.9%)

Anterior + Intermediate

n = 6 (15.4%)

Intermediate

n = 1 (2.6%)

Panuveitis

n = 2 (5.1%)

Initial BCVA (LogMAR)

Mean: 0.179 (SD 0.310) Range: 0–1.30

Worst BCVA (LogMAR)

Mean: 0.312 SD:0.616 Range: 0.3

Worst Cell Count (A.C.) (N = 38)

0 + 

n = 18 (47.4%)

0.5 + 

n = 9 (23.7%)

1 + 

n = 4 (10.5%)

2 + 

n = 2 (5.3%)

3 + 

n = 1 (2.6%)

4 + 

n = 4 (10.5%)

Worst Flare (A.C.) (N = 38)

0

n = 32 (84.2%)

0.5 + 

n = 2 (5.3%)

1 + 

n = 2 (5.3%)

2 + 

n = 2 (5.3%)

3 + 

n = 2 (5.3%)

4 + 

n = 0

Worst Cell Count (Vitreous) (N = 36)

0 + 

n = 18 (50%)

0.5 + 

n = 6 (16.7%)

1 + 

n = 7 (19.4%)

2 + 

n = 4 (11.1%)

3 + 

n = 1 (2.8%)

4 + 

n = 0

Worst Vitreous Haze (N = 39)

0

n = 25 (67.6%)

0.5 + 

n = 3 (8.1%)

1 + 

n = 3 (8.1%)

2 + 

n = 3 (8.1%)

3 + 

n = 1 (2.7%)

4 + 

n = 2 (5.4%)

Keratic precipitates

n = 10 (25.6%)

Intraocular hypertension

n = 7 (17.9%)

Intraocular hypotension

n = 5 (12.8%)

Scleritis

n = 3 (7.7%)

Hypopion

n = 1 (2.6%)

Recurrences (n of recurrences during the follow up)

Mean: 1.8 Range: 0–4

# Recurrences (N = 39)

0

n = 2 (5.7%)

1

n = 13 (37.1%)

2

n = 11 (31.4%)

3

n = 8 (22.9%)

4

n = 1 (2.9%)